Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 601–700 of 1,004
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
Guardamagna, M., Berciano‐Guerrero, M., González, B. V., Pérez-Ruiz, E., Oliver, J., Lavado-Valenzuela, R., Rueda‐Domínguez, A., Barragán, I., & Queipo‐Ortuño, M. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911990 · Cited by 18
“[27] Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella Enhanced efficacy of ICI Increased inosine and anti-tumor T cells”
Liu, C., Zhuang, L., Song, Z., Fan, X., Shao, H., Schönke, M., Boon, M. R., Rensen, P. C. N., & Wang, Y. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.009 · Cited by 19
The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate
Chen, Z., Wang, Z., Du, Y., Shi, H., & Zhou, W. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188826 · Cited by 17
Purine-ifying uric acid by gut microbes
Grelska, A., Sharan, D., & Light, S. H. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.022 · Cited by 17
Effects of dietary arsenic exposure on liver metabolism in mice
Shao, J., Lai, C., Zheng, Q., Luo, Y. H., Li, C., Zhang, B., Sun, Y., Liu, S., Shi, Y., Li, J., et al. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116147 · Cited by 19
Tang, L., Yang, X., Zhou, M., Feng, L., Ji, C., Liang, J., Zhang, B., Shen, R., & Wang, L. (2024) · mSystems · doi:10.1128/msystems.00138-24 · Cited by 20
“Inosine could be released by some gut bacteria, such as Bifidobacterium pseudolon gum and Akkermansia muciniphila (34).”
BackgroundMetabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Li, D., Lan, X., Xu, L., Zhou, S., Luo, H., Zhang, X., Yu, W., Yang, Y., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552010 · Cited by 20
“Another study showed that inosine improved the ef fi cacy of monoclonal antibodies against CTLA-4 and against PD-L1 in mouse models of bladder and small bowel cancer (130).”
Cai, X., Cho, J. Y., Chen, L., Liu, Y., Ji, F., Salgado, K., Ge, S., Yang, D., Yu, H., Shao, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112162 · Cited by 21
“Of note, Mager et al. 59 identify ino-sine as a metabolite produced by A . muciniphila and Bifidobac-terium pseudolongum that markedly increases the level of intra-tumoral and splenic CD4 + and CD8 + T cells and further enhances the efficacy of ICI therapy in a mouse model.”
Qiao, S., Li, T.-T., Jeong, M., Chuanfa, L. I. U., Mizutani, S., Hwang, S.-M., Li, Y., Lyu, M., Nishiyama, K., Tang, Y.-A., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2025.12.003 · Cited by 17
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Gubbi, S., Vijayvergia, N., Yu, J. Q., Kłubo-Gwieździńska, J., & Koch, C. A. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1908-7790 · Cited by 17
“Studies in mouse models have revealed that the effects of ICIs are potentially modulated by the gut microbiome, which is in part mediated through certain microbiome-derived metabolites such as inositol [134].”
Feng, R., Fan, Y., Chen, L., Ge, Q., Xu, J., Yang, M., & Chen, K. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114214 · Cited by 18
Mattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Qian, J., Zhang, X., Wei, B., Tang, Z., & Zhang, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188943 · Cited by 17
Microbiome Alterations and Alzheimer’s Disease: Modeling Strategies with Transgenic Mice
López-Villodres, J. A., Escamilla, A., Mercado-Sáenz, S., Alba-Tercedor, C., Rodríguez‐Pérez, L., Arranz‐Salas, I., Sanchez-Varo, R. M., & Bermúdez, D. (2023) · Biomedicines · doi:10.3390/biomedicines11071846 · Cited by 20
“The role of gut microbiota in the efficacy of checkpoint blockade immunotherapy has also been described in cancer research [34].”
BackgroundLifestyle and host determinants of antitumor immunity and cancer health disparities
Swaby, A. M., Atallah, A., Varol, O., Cristea, A., & Quail, D. F. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.007 · Cited by 19
Yang, H., Shi, P., Li, M., Kong, L., Liu, S., Jiang, L., Yang, J., Xu, B., Yang, T., Xi, S., et al. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115660 · Cited by 23
Microbiota configuration determines nutritional immune optimization
Han, S., Stacy, A., Corral, D., Link, V. M., Siqueira, M. K. D., Chi, L., Teijeiro, A., Yong, D., Pérez‐Chaparro, P. J., Bouladoux, N. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304905120 · Cited by 17
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
Microbiota and metabolite alterations in pancreatic head and body/tail cancer patients
Zhu, Y., Liang, X., Zhang, G., Li, F., Xu, J., Ma, R., Chen, X., Ma, M., Wang, Y., Chen, C., et al. (2024) · Cancer Science · doi:10.1111/cas.16238 · Cited by 18
“25 Whether these differential microbiota are involved in the occurrence of PHC and PBTC needs to be further studied.”
BackgroundPotential role of the intratumoral microbiota in colorectal cancer immunotherapy
Fan, S., Zhang, W., Zhou, L., Wang, D., & Tang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112537 · Cited by 16
Wu, Y., Xiong, J., Zhan, C.-N., & Xu, H. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106889 · Cited by 19
Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis
Permain, J., Hock, B. D., Eglinton, T. I., & Purcell, R. V. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10215-5 · Cited by 18
“The efficacy of PDL1 targeted immunotherapy was also increased when mice were colo-nised with B. pseudolongum, but not to the same extend as observed for CTLA4 therapy [88].”
BackgroundImpact of the Lung Microbiota on Development and Progression of Lung Cancer
Belaïd, A., Roméo, B., Rignol, G., Benzaquen, J., Audoin, T., Vouret‐Craviari, V., Brest, P., Varraso, R., von Bergen�, M., Marquette, C., et al. (2024) · Cancers · doi:10.3390/cancers16193342 · Cited by 18
Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota
Green, G. B. H., Cox-Holmes, A. N., Potier, A. C. E., Marlow, G. H., & McFarland, B. C. (2024) · Biomedicines · doi:10.3390/biomedicines12112429 · Cited by 16
Luo, B., An, Q., Lei, J., Tan, D., Liu, X., Li, H., Zhao, Y., Qin, J., Zhang, C., Zhang, Y., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2447821 · Cited by 21
“30”
Circadian Rhythm Modulation of Microbes During Health and Infection
Pearson, J. A., Voisey, A., Boest-Bjerg, K., Wong, F. S., & Li, W. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.721004 · Cited by 20
“…species can enhance the success of therapy with immune checkpoint blockade in mice and cancer patients (Sivan et al., 2015; Vétizou et al., 2015; Mager et al., 2020) and gut bacteria could also enhance the responses to chemotherapy via modulating the tumor microenvironment and immune cell…”
BackgroundGut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy
Cheng, P., Shen, P., Shan, Y., Yu, Y., Deng, R., Chen, W., Lu, Y., & Wei, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626045 · Cited by 17
Jingushi, K., Kawashima, A., Saito, T., Kanazawa, T., Motooka, D., Kimura, T., Mita, M., Yamamoto, A., Uemura, T., Yamamichi, G., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03213-5 · Cited by 16
Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer
Yan, X.-D., Bai, L., Qi, P., Lv, J., Song, X., & Zhang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411387 · Cited by 16
“Additionally, inosine can activate type 1 helper (Th1) cells through the adenosine 2A receptor, stimulated by DCs, and enhance the therapeutic effect on tumors in the presence of ICIs [51].”
BackgroundInfluentialChandrasekaran, P., Krausz, M., Han, Y., Mitsuiki, N., Gabrysch, A., Nöltner, C., Proietti, M., Heller, T., Grou, C., Calderon, V., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02028-7 · Cited by 16
“Although several key studies have demonstrated the important role of the microbiota [16, 17] and associated metabolites [18, 19] in mediating response to CTLA4 blockers to treat malignancies, where T reg activity is intentionally dampened, no studies to date have evaluated the role of the…”
Zhou, Z., Lv, Y., Zuo, A., Zhu, X., Xu, Y., Zuo, L., Xu, H., Liu, S., Zhang, Y., Weng, S., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.05.008 · Cited by 16
“However, in the presence of exogenous IFN - g , inosine promotes Th1 differentiation through A 2A R-dependent signaling and enhances anti-tumor immunity in various cancer types, such as CRC, melanoma, and bladder cancer [200].”
Zhou, P., Zhang, W., Liao, Y., Zhai, Z., Lu, S., Jiang, S., Hu, W., & Gong, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002573 · Cited by 18
Autoimmunity: A New Focus on Nasal Polyps
Huang, J., & Xu, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098444 · Cited by 18
Jaye, K. M., Alsherbiny, M. A., Chang, D., Li, C. G., & Bhuyan, D. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015053 · Cited by 18
“Inosine is produced via the metabolic conversion of adenosine by the adenosine deaminase enzyme [1] and also by certain gut microbial species including Bifidobacterium pseudolongum [3].”
BackgroundGut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas
Meléndez-Vázquez, N. M., Nguyen, T. T., Fan, X., Lopez-Rivas, A. R., Fueyo-Margareto, J., Gomez‐Manzano, C., & Godoy‐Vitorino, F. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200787 · Cited by 19
Jiang, N., Zhao, K., Liu, C., Zhu, X., Huang, X., Yang, L., Yi, X., Zhuang, Y., Ye, B., Qian, J., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150820 · Cited by 19
Ji, G., Zhao, J., Si, X., & Song, W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115345 · Cited by 18
Meng, Y., Sun, J. Y., & Zhang, G. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104403 · Cited by 16
Integrating functional metagenomics to decipher microbiome–immune interactions
Sardar, P., Almeida, A., & Pedicord, V. A. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12798 · Cited by 16
Xu, Y., Wu, X., Li, Y., Liu, X., Fang, L., & Jiang, Z. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2403.03056 · Cited by 17
Du, C., Zhao, Y., Shen, F., & Qian, H. (2024) · Foods · doi:10.3390/foods13223704 · Cited by 15
Host Microbiomes in Tumor Precision Medicine: How far are we?
D’Amico, F., Barone, M., Tavella, T., Rampelli, S., Brigidi, P., & Turroni, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220105121754 · Cited by 17
Food for healthier aging: power on your plate
Mafra, D., Ugochukwu, S. A., Borges, N. A., Cardozo, L., Stenvinkel, P., & Shiels, P. G. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2107611 · Cited by 16
“Inosine (a metabolite that regulates mucosal and systemic immune cells) is produced by specific gut microbiota, which links microbe-induced metabolite synthesis and the efficacy of immunotherapy (Mager et al. 2020).”
BackgroundNutrition and Microbiome Interactions in Human Cancer
Daschner, P. J., Ross, S., Seifried, H. E., Kumar, A., & Flores, R. (2022) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.10.004 · Cited by 14
Change in the Gut Microbiome and Immunity by Lacticaseibacillusrhamnosus Probio-M9
Zhang, M., Zheng, Y., Sun, Z., Cao, C., Zhao, W., Liu, Y., Zhang, W., & Zhang, H. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03609-22 · Cited by 16
Hoyd, R., Wheeler, C. E., Liu, Y., Singh, M. S. J., Muniak, M., Jin, N. Y., Denko, N. C., Carbone, D. P., Mo, X. M., & Spakowicz, D. J. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0435 · Cited by 16
“Bifidobacterium is a common gut commensal that was shown to affect the response to immune checkpoint blockade via the secretion of inosine, which is takenupbyimmunecellsviatheadenosinereceptorA2AAR(33).”
BackgroundVirtanen, S., Saqib, S., Kanerva, T., Ventin-Holmberg, R., Nieminen, P., Holster, T., Kalliala, I. E. J., & Salonen, A. (2024) · Microbiome · doi:10.1186/s40168-024-01993-9 · Cited by 15
Weis, A. M., Bauer, K. M., Tang, W. W., Victor, E. S., Bell, R. S., Brown, D. G., Ekiz, H. A., Tran, V., Klag, K. A., Swanson, E. A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116172 · Cited by 16
González-Brito, A., & Uribe‐Herranz, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1083303 · Cited by 14
“In a study investigating four different murine cancer models, inosine, a bacterial purine metabolite produced by Bifidobacterium pseudolongus, promoted Th1 activation and antitumor immunity which improved the antitumor effects (56).”
BackgroundBouferraa, Y., Fares, C., Zerdan, M. B., & Kennedy, L. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119702 · Cited by 15
“In contrast to adenosine, inosine has proinflammatory effects on the adenosine A2A receptor, supporting the TH1 and its anti-tumor effects in the mice [53].”
BackgroundCisplatin and doxorubicin chemotherapy alters gut microbiota in a murine osteosarcoma model
Tian, Z., Qiao, X., Wang, Z., Li, X., Pan, Y., Wei, X., Lv, Z., Li, P., Du, Q., Wei, W., et al. (2024) · Aging · doi:10.18632/aging.205428 · Cited by 16
“Colidextri-bacter produces inosine [30], which is involved in energy metabolism as a physiological energy source and possesses a wide range of anti-inflammatory and immunomodulatory properties, including promoting anti-inflammatory cytokine production and inhibiting the production of chemokines and…”
BackgroundThe impact of purine nucleosides on neuroplasticity in the adult brain
dos Santos, B., Piermartiri, T., & Tasca, C. I. (2024) · Purinergic Signalling · doi:10.1007/s11302-024-09988-9 · Cited by 15
“INO has been shown to possess anti‑inflammatory properties [94], anti‑tumoral effects [95], and the ability to modulate immune responses [64, 96].”
Blood lipids mediate the effects of gut microbiome on endometriosis: a mendelian randomization study
Su, C., Wan, S., Ding, J., Ni, G., & Ding, H. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02096-y · Cited by 15
“However, studies have demonstrated that Olsenella can enhance the activity of anti-PD-1 antibodies by producing the metabolite inosine to activate antitumor T cells [49].”
BackgroundTargeting gut microbiota for immunotherapy of diseases
Yu, Y., Liu, X., Liao, C., Yu, R., Wang, X., Li, M., & Wang, Y. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03770-x · Cited by 15
“Inosine is the metabolic product of Bifidobacterium pseu-dopodium and Akkermansia muciniphila , which activates immune cells and stimulates metabolism (Mager et al. 2020).”
Cui, C., Yang, T., Wang, S., Jia, Z., Zhao, L., Sun, X., Sun, X., Zong, J., Wang, S., & Chen, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304403 · Cited by 15
Xue, K., Li, J., & Huang, R. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1411249 · Cited by 16
“According to a recent study, Pseudomonas aeruginosa produces the metabolite adenosine, followed by tumor-in fi ltrating IFN-g + CD4+ and IFN-g + CD8+ T cells, enhancing immune therapy response, and improving the ef fi cacy of checkpoint blockade immunotherapy (Mager et al., 2020).”
MethodAkkermansia muciniphila Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer
Yu, Y., Li, L., Yang, Q., Xue, J., Wang, B., Xie, M., Shangguan, W., Zhu, Z., & Wu, P. (2024) · Microorganisms · doi:10.3390/microorganisms12081653 · Cited by 18
“However, it was worth noting that supplementing inosine alone had no anti-tumor effect [45].”
BackgroundCheng, W., Zhu, N., Wang, J., & Yang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331518 · Cited by 14
“In addition, bacteria such as Akkermansia muciniphila (A. muciniphila), Bacteroides (B) fragilis , Bi fi dobacterium pseudolongum (B. pseudolongum) , Clostridiales SPP., Eleven SPP. and Lactobacillus species signi fi cantly enhance ef fi cacy of ICBs in the cancer (128 – 130).”
BackgroundLi, H., Gong, Y., Yan, P., Xu, Y. J., Qin, G., Wen, W., & Teng, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1453753 · Cited by 23
“It has revealed the complex relationship between commensal bacteria and the host immune system (141, 142).”
Li, J., Jia, J., Teng, Y., Wang, X., Xia, X., Song, S., Zhu, B., & Xia, X. (2025) · Foods · doi:10.3390/foods14030387 · Cited by 14
“Inosine, a bacterial metabolite that can be produced by Bifidobacterium pseudolongum , could activate Th1 through adenosine receptor signaling and activate effector T cells [37].”
A surgical method for continuous intraportal infusion of gut microbial metabolites in mice
Orabi, D., Osborn, L. J., Fung, K., Massey, W. J., Horak, A. J., Aucejo, F., Choucair, I., DeLucia, B., Wang, Z., Claesen, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145607 · Cited by 14
“Disease states, including cardiovascular disease, chronic kidney disease, diabetes, cancer, and cancer therapeutic efficacy, all contain a demonstrable microbial metabolite component (3–7).”
Toll-like receptors, environmental caging, and lung dysbiosis
Lipinski, J. H., Falkowski, N. R., Huffnagle, G. B., Erb‐Downward, J. R., Dickson, R. P., Moore, B. B., & O’Dwyer, D. N. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00002.2021 · Cited by 14
Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches
Pleguezuelos‐Manzano, C., Puschhof, J., & Clevers, H. C. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-095211 · Cited by 19
Liu, W., Zhang, L., Shi, X., Shen, G., & Feng, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.008 · Cited by 17
Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
Wang, J., Ma, X., Ma, Z., Ma, Y., Wang, J., & Cao, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810539 · Cited by 15
Zhang, W., Zhang, J., Liu, T., Xing, J., Zhang, H., Wang, D., & Tang, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04081-3 · Cited by 15
“pseudolongum strain generated inosine, which stimulated cDC-dependent Th1 cell development, considerably increasing the efficacy of ICI (Mager and Burkhard 2020).”
BackgroundThe Microbiome and Liver Cancer
Myojin, Y., & Greten, T. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000646 · Cited by 13
Dissecting the intratumoral microbiome landscape in lung cancer
Zhao, Y. G., Yang, Z., Wu, D., & Hai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1614731 · Cited by 14
“The speci fi c bacterial species present and their ability to modulate immune checkpoints, such as PD-1/PD-L1 (Programmed cell death protein 1/Programmed death-ligand 1) or CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4), can thus have profound effects on the success of immunotherapies (83, 84).”
Hughes, E. R., Panzetta, M. E., Sharma, A., & Valdivia, R. H. (2025) · Annual Review of Microbiology · doi:10.1146/annurev-micro-051524-032131 · Cited by 21
Pratelli, G., Tamburini, B., Carlisi, D., Blasio, A. D., D’Anneo, A., Emanuele, S., Notaro, A., Affranchi, F., Giuliano, M., Seidita, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914619 · Cited by 16
The Microbiome Matters: Its Impact on Cancer Development and Therapeutic Responses
Chung, I.-Y., Kim, J. H., & Koh, A. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00110-7 · Cited by 15
“For example, inosine produced by intestinal Bifidobacterium pseudolongum (Mager et al., 2020) and desaminotyrosine produced by flavonoids-degrading bacteria (Joachim et al., 2023) were found to significantly enhance the responses of ICIs by activating antitumor T cells in preclinical models.”
Chang, C.-C., Liu, T.-C., Lu, C.-J., Chiu, H., & Lin, W. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.025 · Cited by 14
“Mager et al. demonstrated that inosine derived from gut microbiota enhanced the efficacy of immune checkpoint inhibitors by activating antitumor T cells [48].”
BackgroundTargeting G Protein–Coupled Receptors in Immuno-Oncological Therapies
Stagg, J., & Gutkind, J. S. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080852 · Cited by 14
Self-citationShaikh, F. Y., Lee, S., White, J. R., Zhao, Y., Ferri, J. T., Pereira, G., Landon, B. V., Ke, S., Hu, C., Feliciano, J. L., et al. (2024) · Cancers · doi:10.3390/cancers16213644 · Cited by 17
“A number of metabolites produced by or linked to microbes, such as short chain fatty acids, inosine, and trimethylamine N-oxide, have been implicated in other tumor types as modulators of immune cell function in the setting of ICI treatment [20–23].”
BackgroundAltrawy, A., Khalifa, M. M., Abdelmaksoud, A., khaled, Y., Saleh, Z. M., Sobhy, H., Abdel-Ghany, S. E., Alqosaibi, A. I., Almuhanna, A., Almulhim, J., et al. (2024) · Cancers · doi:10.3390/cancers16244132 · Cited by 15
Regulating the Tumor Microbiome through Near-Infrared-III Light-Excited Photosynthesis
Li, F., Zheng, B., Chen, J., Yan, Q., Lu, Z., Fang, C., Fu, Y., & Li, X. (2025) · ACS Nano · doi:10.1021/acsnano.4c18954 · Cited by 14
Reens, A. L., Cabral, D. J., Liang, X., Norton, J. E., Therien, A. G., Hazuda, D. J., & Swaminathan, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643255 · Cited by 16
Vitamin K2 Enhances Fat Degradation to Improve the Survival of C. elegans
Qu, Z., Zhang, L., Huang, W. M., & Zheng, S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.858481 · Cited by 14
Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement
Kuo, A. M.-S., Kraehenbuehl, L., King, S., Leung, D. Y. M., Goleva, E., Moy, A. P., Lacouture, M. E., Shah, N. J., & Faleck, D. M. (2022) · Cancers · doi:10.3390/cancers14122995 · Cited by 13
“It has been noted that the frequency of PD-1 expressing CD8 cells relative to PD-1 expressing T-regs can predict the clinical efficiency of PD-1 blockade therapies, suggesting that the variability in PD-1 expression on regulatory and effector T-cells may influence the development of irAEs while on ICB [31].”
BackgroundInfluentialImpact of the Host Microbiome on Vaccine Responsiveness: Lessons Learned and Future Perspective
Stefanetti, G., & Kasper, D. L. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00309 · Cited by 14
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding
Wong, C. C., Fong, W., & Yu, J. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.017 · Cited by 13
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors
Pei, B., Ma, X., Wu, N., Wang, C., & Yang, W. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.05 · Cited by 13
Li, X., Jia, Y., Li, Y., Hei, H., Zhang, S., & Qin, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582166 · Cited by 16
“Conversely, certain commensals like Bi fi dobacterium pseudolongum , Lactobacillus johnsonii , and Olsenella species enhance anti-tumor immunity through inosine-mediated T cell activation (24).”
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 18
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 15
“The metabolic landscape of the GI TME is uniquely complex, defined by a tripartite interplay involving intense competition for nutrients and intricate metabolic exchanges between host cells, tumor cells, and the resident gut microbiota [205].”
Pandey, P., & Khan, F. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130401 · Cited by 13
The role of microbiota in tumorigenesis, progression and treatment of bladder cancer
Peng, Z., Zhuang, J., & Shen, B. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.47 · Cited by 15
Xu, J., Wang, J., He, Y., Chen, R., & Meng, Q. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122977 · Cited by 14
Paola, F. J. D., Alquati, C., Conti, G., Calafato, G., Turroni, S., D’Amico, F., Ceccarelli, C., Buttitta, F., Bernardi, A., Cuicchi, D., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05305-5 · Cited by 13
“The latter has been suggested to be involved in the development of CRC and to interfere with the efficacy of immune checkpoint inhibitors [33, 34].”
BackgroundThe Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy
Wang, C., Feng, Q., Shi, S., Qin, Y., Lu, H., Zhang, P., Liu, J., & Chen, B. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401538 · Cited by 15
Chambers, L., Grencewicz, D. J., & Spakowicz, D. J. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.015 · Cited by 13
Intratumoral microbiota as a novel prognostic indicator in bladder cancer
Zhang, Y., Lin, H., Liang, L., Jin, S., Lv, J. G., Zhou, Y.-H., Xu, F., Liu, F., & Feng, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-72918-7 · Cited by 15
“Some microbial metabolites that accumulate in tumors, such as fatty acids and adenosine, have also been shown to bind to key receptors on cancer cells and immune cells 10–12 .”
BackgroundPredictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
Yao, J., Lin, X., Zhang, X., Xie, M., Ma, X., Bao, X., Song, J., Liang, Y., Wang, Q., & Xue, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2406063 · Cited by 14
Identification of intratumoral bacteria that enhance breast tumor metastasis
Gerbec, Z. J., Serapio-Palacios, A., Metcalfe‐Roach, A., Krekhno, Z., Bar‐Yoseph, H., Woodward, S. E., Peña-Díaz, J., Nemirovsky, O., Awrey, S. J., Moreno, S. H., et al. (2025) · mBio · doi:10.1128/mbio.03595-24 · Cited by 16
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Islam, T., Sagor, M. S., Tamanna, N. T., Bappy, M. K. I., Danishuddin, M., Haque, M. A., & Lackner, M. K. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15030112 · Cited by 16
“B. pseudolongum modified improved immunotherapy responses by way of inosine production [67].”
Feng, Y., Han, M.-Z., Zhou, Y., Wang, Y., Wang, Y., Sun, T., & Xu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575963 · Cited by 13
“Inosine induces T helper 1 (Th1) cell activation in a microenvironment-dependent manner via the T cell-speci fi c adenosine A2A receptor (A2AR) signaling pathway, while the inosine-A2AR axis mediates the therapeutic potentiation of immune checkpoint blockade (ICB) (83).”
The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies
Wei, Z., Gao, G., He, Q., Kwok, L. Y., & Sun, Z. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.038 · Cited by 14
“For example, Bifidobacterium pseudolongum , isolated from colorectal tumors, has been shown to enhance a conventional DC-dependent TH1 cell circuit, significantly improving ICB efficacy in mouse models of intestinal and epithelial tumors[144].”
Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy
Tian, M., Zhang, S., Tseng, Y., Shen, X., Dong, L., & Xue, R. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210706110713 · Cited by 12
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.